Founded in 2016, Qure.AI operates as a private company. The stock is not listed on any public market.
Qure.AI has no published valuation.
Lightspeed Venture PartnersLEAD3360 ONE AssetLEADPPeak XV PartnersLEADBBill & Melinda Gates FoundationLEADMMerck Global Health Innovation FundKKae CapitalLightspeed Venture Partners360 ONE AssetQure.ai is a health tech company based in Mumbai, India, founded in 2016, that uses deep learning and artificial intelligence to make diagnostic imaging more accessible. Its FDA-cleared solutions, spanning 26 cleared indications, help identify and manage conditions including lung cancer, tuberculosis, pediatric TB and stroke, supporting radiologists, pulmonologists and emergency physicians in real-world clinical workflows.
The company has raised $130 million in capital, was the first AI company to be featured in the Lancet in 2018, and partners with Microsoft to expand access to its lung cancer detection and management suite in the United States.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Qure.AI.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Qure.AI availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Qure.AI included.
Qure.ai is a health tech company based in Mumbai, India, founded in 2016, that uses deep learning and artificial intelligence to make diagnostic imaging more accessible.
Qure.AI is private, so its shares are not available on public markets.
Qure.AI launched in 2016.
Qure.AI has raised $125.3M across 5 funding rounds.
Bill & Melinda Gates Foundation led Qure.AI's most recent round.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
